Criteria Bio Ventures is a Life Sciences venture fund that backs private biotech companies in Europe and North America, with a special focus on Spain and Portugal. It invests across modalities and disease areas, offering support until achieving meaningful impact.

Criteria Bio Ventures

Criteria Bio Ventures | 593 followers on LinkedIn. Pushing the limits of science to revolutionize healthcare | Criteria Bio Ventures is a leading life sciences venture fund looking to partner with transformative companies to shape the future of healthcare. 

We team up with driven entrepreneurs and fellow investors who aim to revolutionize healthcare through disruptive and well-protected innovations that have the potential to transform patients’ lives where there is a significant unmet medical need.

We invest in private biotech companies in Europe and North America, with special focus in Spain and Portugal.

Life Science Investor @ Criteria Bio Ventures

Salvatore Cappadona

Life Science Investor | Venture Capital | Corporate Strategy | Biotech company builder

Ruben Sebastian

Next week, the Criteria Bio Ventures team will be in Stockholm for BIO-Europe, connecting with biotech entrepreneurs, industry leaders, and fellow VC investors. We’re looking forward to engaging with #biopharma colleagues who are driving change in Life Sciences. If you’re also attending, reach out to Pablo Cironi or Salvatore Cappadona to set up a meeting! 🤝 EBD Group | Criteria Bio Ventures | Caixa Capital Risc #BIOEurope #partnering #biotech #pharma #innovation #venturecapital #lifesciences

Congratulations to MedLumics on their progress in advancing cardiac care! Enrolling the first patients in the First-in-Human trial with the AblaView Pulsed Field Ablation System marks a significant step forward in atrial fibrillation treatment. This milestone highlights the power of OCT technology to provide real-time insights during PFA ablations, which could lead to better outcomes for AFib patients. Looking forward to seeing the impact of this innovation! #MedLumics #AtrialFibrillation #InnovationInHealthcare #ClinicalTrials #OCTTechnology

We are pleased to announce that Criteria Bio Ventures has participated in the oversubscribed $17.2M seed financing of Tolerance Bio , a biopharmaceutical company pioneering thymus-based therapies for immune-mediated diseases. Seasoned biotech executive Francisco Leon MD, PhD, co-founder and CEO of Tolerance Bio, will lead an experienced executive team with deep industry expertise to develop novel approaches to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance. Previously, Francisco was co-founder & CSO of Provention Bio (acquired by Sanofi) and co-founder, CEO & CMO of Celimmune (acquired by Amgen). Headquartered in Philadelphia, Tolerance Bio is developing an allogeneic, or “off the shelf”, thymus induced pluripotent stem cell (iPSC)-based cell therapy platform along with pharmacological thymus therapies to address immune-mediated diseases caused by abnormalities in immune tolerance, including autoimmunity, immune deficiencies, transplant rejection, cancer and allergies. The iPSC technologies were initially developed at the University of Colorado and the University of Florida by Holger A. Russ , PhD, scientific co-founder and Associate Professor at the University of Florida. As part of this financing, Pablo Cironi , PhD, Director at Criteria Bio Ventures, joins Tolerance Bio’s Board of Directors. We are proud to welcome Tolerance Bio to our portfolio and support its innovative programs in the exciting field of thymus-based therapies! Pablo Cironi | Ruben Sebastian Learn more about Tolerance Bio and this financing here: https://lnkd.in/dd2mtAzG #portfolionews #portfoliocompany #venturecapital #biotech #lifesciences #financing #immunology #autoimmunity

Excited to welcome Tolerance Bio to our portfolio! It has been a pleasure leading the due diligence, and I’m already looking forward to supporting Tolerance’s stellar team on their journey at the forefront of innovation developing thymus-based therapies for immune-mediated diseases. Criteria Bio Ventures has co-led the oversubscribed $17.2M seed financing of Tolerance Bio (Philadelphia, USA), alongside Columbus Venture Partners. Under the leadership of Francisco Leon , CEO & co-founder of Tolerance Bio, and former co-founder & executive at Provention Bio (acquired by Sanofi for $2.9B in 2023) and Celimmune (acquired by Amgen ), Tolerance is developing an allogeneic, “off the shelf” thymus #iPSC based #celltherapy platform, as well as pharmacological therapies aimed at preserving, restoring, and manipulating the function of the #thymus to address immune-mediated diseases caused by abnormalities in immune tolerance. As an early-stage investor, Tolerance Bio exemplifies the type of company that truly motivates me to wake up every day and contribute to bringing novel #medicines closer to patients. Tolerance embodies the true meaning of disruptive innovation, guided by serial drug hunters and developers. 🔗 Read the full press release here: https://lnkd.in/d5-vjHvv Criteria Bio Ventures | Tolerance Bio | Francisco Leon | Holger A. Russ #portfolionews #venturecapital #biotech #innovation #lifesciences #financing #immunology #regeneration #autoimmunity #cancer

Impulsamos la construcción del CaixaResearch Institute , centro de investigación de la Fundación ”la Caixa” , firmando un préstamo de 80 millones de euros con el European Investment Bank (EIB) . Desde #CriteriaCaixa , recibiremos la financiación y haremos llegar los fondos para ejecutar este primer centro de #investigación #biomédica de España dedicado al estudio interdisciplinar de la inmunología con sede en Barcelona. Este acuerdo ha sido firmado por nuestro consejero delegado Ángel Simón , el director de la Fundación, Antonio Vila, y el director general de Operaciones para la UE del BEI, Jean-Christophe Laloux . Descubre más sobre este acuerdo y conoce este proyecto que está destinado a convertirse en un polo de referencia europeo. 📝 https://lnkd.in/d4F49SQi

CriteriaCaixa

Impulsaremos la cartera de capital privado hasta los 4.000 millones de euros, en el marco de nuestro #PlanEstratégicoCriteriaCaixa , con el objetivo de dinamizar la economía industrial. En el foro #BCNDesperta , organizado por Crónica Global, Metrópoli Abierta y EL ESPAÑOL , nuestro consejero delegado Ángel Simón ha mantenido un diálogo con el periodista Arturo Criado Gea sobre la importante hoja de ruta que supone este plan para invertir en empresas con capacidad de crecimiento, innovación e internacionalización, que sigan los criterios ambientales, sociales y de buen gobierno. Con el objetivo de conseguir en 2030 un valor bruto de los activos de 40.000 millones de euros, la cartera de capital privado representará un 10 % para impulsar las pequeñas y medianas empresas que juegan un papel activo en la industrialización del país.

Earlier today, our team members Ruben Sebastian-Perez and Salvatore Cappadona participated in the Early-Stage Therapeutics and Oncology Innovation panels at #RESIEurope2024 . We shared success stories and experiences from our portfolio and discussed exciting trends we are closely monitoring with great interest in oncology, metabolic diseases, autoimmunity, cardio, and beyond! Reach out to our team attending if you would like to exchange thoughts on innovative therapeutic opportunities. Salvatore Cappadona | Ruben Sebastian-Perez | Sebastián Chiavenna #RESIEurope #biotech #innovation #venturecapital

Ha sido un placer participar en el #InformeAseBio2023 "25 años de biotecnología", presentado ayer, y que detalla los principales indicadores del sector biotecnológico en España y su evolución en el último cuarto de siglo. Felicitamos a AseBio - Asociación Española de Bioempresas por sus 25 años de trabajo dedicado a fortalecer el sector biotecnológico en España y a todos aquellos que han contribuido a fortalecer un sector que impacta significativamente en la calidad de vida de las personas y en el crecimiento económico y social. Enhorabuena Ion Arocena y a todo el equipo de ASEBIO por el esfuerzo y dedicación para que la biotecnología en España sea un actor de relevancia. #ASEBIO #Biotech #Pharma

🌟 Exciting news on our portfolio company Minoryx Therapeutics ! 🌟 We are pleased to share groundbreaking findings recently published in Brain by #Minoryx team and Dr. Fanny Mochel, who led the clinical study. The study reveals that #leriglitazone has demonstrated remarkable efficacy in halting disease progression in adult patients with progressive #cALD , a devastating neurodegenerative disorder characterized by demyelinating brain lesions. This breakthrough marks a significant advancement in our understanding and treatment of #cALD , offering hope to those affected and their families. It underscores the power of innovative research and collaboration in pushing the boundaries of medicine. Kudos to the dedicated researchers and healthcare professionals involved in this critical work. Your commitment to improving patient outcomes is truly inspiring. Let's continue to support and accelerate research efforts towards finding effective treatments for neurodegenerative diseases. https://lnkd.in/dJbbR3H9 #Neurology #BrainHealth #HealthcareInnovation #Biotech #VC

Metric
Company Name	Criteria Bio Ventures
Symbol
MSH ID	COM:CRITERIABIOVENTURES
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital & Private Equity
Country	ES
Stage
Employee Count
Website	criteriabioventures.com
LinkedIn	criteria-bio-ventures
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	84
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CRIT

COM:CRITERIABIOVENTURES

Criteria Bio Ventures

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue